Journal of internal medicine
-
Antithyroid antibodies increase the likelihood of developing overt hypothyroidism, but their clinical utility remains unclear. No large randomized controlled trial (RCT) has assessed whether older adults with subclinical hypothyroidism (SHypo) caused by autoimmune thyroid disease derive more benefits from levothyroxine treatment (LT4). ⋯ Among older adults with SHypo, positive antithyroid antibodies are not associated with more benefits on clinical outcomes with LT4.